
Please try another search
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 3rd:
Dropbox, Inc. (DBX): This company that provides a collaboration platform has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 26.3% over the last 60 days.
Dropbox’s shares gained 14.1% over the last one month against the S&P 500’s decline of 4%. The company possesses a Momentum Score of A.
NanoString Technologies, Inc. (NSTG): This company that provides life science tools for translational research and molecular diagnostic products has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 19.3% over the last 60 days.
NanoString Technologies shares gained 25% over the last one month. The company possesses a Momentum Score of B.
PRA Group, Inc. (PRAA): This financial and business services company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.8% over the last 60 days.
PRA Group’s shares gained 7.9% over the last one month. The company possesses a Momentum Score of B.
Cardinal Health (NYSE:CAH), Inc. (CAH): This integrated healthcare services and products company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.5% over the last 60 days.
Cardinal Health’s shares gained 5.4% over the last one month. The company possesses a Momentum Score of B.
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Through many years of frustration among gold bugs due to the failure of gold stock prices to leverage the gold prices in a positive way, there were very clear reasons for that...
I know there is the smell of fear in the air when I see my readership double as we reach a point where weekly chart factors come into play. Up until last week, markets have...
Professional traders get paid because of one skill and one skill only: the ability to foresee what the world (or the economy, at least) might look like in six to nine months....
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.